BRPI0819908A2 - Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona - Google Patents

Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona

Info

Publication number
BRPI0819908A2
BRPI0819908A2 BRPI0819908-6A BRPI0819908A BRPI0819908A2 BR PI0819908 A2 BRPI0819908 A2 BR PI0819908A2 BR PI0819908 A BRPI0819908 A BR PI0819908A BR PI0819908 A2 BRPI0819908 A2 BR PI0819908A2
Authority
BR
Brazil
Prior art keywords
chloridate
formulations
solutions containing
topical ophthalmic
dexamethasone phosphate
Prior art date
Application number
BRPI0819908-6A
Other languages
English (en)
Inventor
Onkar N Singh
Suresh C Dixit
Michael Wall
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI0819908A2 publication Critical patent/BRPI0819908A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0819908-6A 2007-11-27 2008-11-24 Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona BRPI0819908A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99045207P 2007-11-27 2007-11-27
PCT/US2008/084532 WO2009070530A1 (en) 2007-11-27 2008-11-24 Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate

Publications (1)

Publication Number Publication Date
BRPI0819908A2 true BRPI0819908A2 (pt) 2015-05-19

Family

ID=40467276

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819908-6A BRPI0819908A2 (pt) 2007-11-27 2008-11-24 Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona

Country Status (16)

Country Link
US (2) US7888370B2 (pt)
EP (1) EP2211835A1 (pt)
JP (1) JP2011504881A (pt)
KR (1) KR20100090278A (pt)
CN (1) CN101861139A (pt)
AR (1) AR069438A1 (pt)
AU (1) AU2008329876A1 (pt)
BR (1) BRPI0819908A2 (pt)
CA (1) CA2703913A1 (pt)
CL (1) CL2008003536A1 (pt)
MX (1) MX2010004953A (pt)
RU (1) RU2010126096A (pt)
TW (1) TW200932285A (pt)
UY (1) UY31494A1 (pt)
WO (1) WO2009070530A1 (pt)
ZA (1) ZA201002884B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2013065029A1 (en) * 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
ITMI20122002A1 (it) * 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
WO2014119643A1 (ja) * 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US11452732B2 (en) * 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) * 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
GR1008921B (el) * 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
CA3023243C (en) * 2016-05-06 2020-01-21 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20190216830A1 (en) * 2017-10-06 2019-07-18 Aciont Inc. Ophthalmic compositions
CN113750041A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 一种地塞米松磷酸钠液体制剂及其制备方法
CN116270662A (zh) * 2021-12-03 2023-06-23 苏州欧康维视生物科技有限公司 盐酸莫西沙星地塞米松磷酸钠滴眼液

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2939873A (en) * 1959-01-26 1960-06-07 Merck & Co Inc Synthesis of steroid phosphates
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
AU2001261748A1 (en) * 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose

Also Published As

Publication number Publication date
US20110082125A1 (en) 2011-04-07
CN101861139A (zh) 2010-10-13
JP2011504881A (ja) 2011-02-17
TW200932285A (en) 2009-08-01
US7888370B2 (en) 2011-02-15
CL2008003536A1 (es) 2009-10-16
EP2211835A1 (en) 2010-08-04
WO2009070530A1 (en) 2009-06-04
US8173671B2 (en) 2012-05-08
UY31494A1 (es) 2009-03-02
RU2010126096A (ru) 2012-01-10
US20090137539A1 (en) 2009-05-28
AR069438A1 (es) 2010-01-20
CA2703913A1 (en) 2009-06-04
MX2010004953A (es) 2010-08-10
KR20100090278A (ko) 2010-08-13
ZA201002884B (en) 2011-07-27
AU2008329876A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
BRPI0819908A2 (pt) Formulações de soluções oftálmicas ou ópticas tópicas contendo cloridato de moxifloxacina e fosfato de dexametasona
FR22C1060I2 (fr) Imidazotriazines et imidazopyrimidines utilisees en tant qu'inhibiteurs de kinases
IL211448A (en) Use of bio-enhancers and/or photo-enhancers for preparing ophthalmic compositions comprising riboflavin or riboflavin phosphate for treating corneal ectasic disorders by corneal cross-linking
IL251768A0 (en) Auris formulations for treating otic diseases and conditions
HRP20182135T1 (hr) Pripravci za i postupci liječenja poremećaja povezanih s ige
EP2432473A4 (en) PYRAZOLOPYRIMIDINES AND CORRESPONDING HETEROCYCLES AS KINASE INHIBITORS
DK2376506T3 (da) Flydende sammensætning indeholdende fosforsyre- eller thiofosforsyretriamidderivat og anvendelse heraf
SMT201600080B (it) Inibitori di chinasi janus per il trattamento di occhio secco e altre malattie oculari
BR112013008140A2 (pt) "compostos imidazotriazinona".
EP2773251A4 (en) DISPENSER AND POLLUTION SENSOR
PT2245145T (pt) Fabrico de enzimas sulfatase lisossómicas humanas altamente fosforiladas e suas utilizações
EP2179060A4 (en) DIFFERENTIAL EXPRESSION OF MICROSIS IN FUNCTIONING COMPARED TO NON-FUNCTIONING HUMAN HEARTS
EP2259678A4 (en) PROTEIN KINASE MODULATORS
PL15177166T1 (pl) Modulatory receptora s1p do leczenia stwardnienia rozsianego
HRP20190059T1 (hr) Pripravci za liječenje boli i/ili upale
EP2187743A4 (en) FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS
EP2547676A4 (en) MODULATORS OF THE HEC1 ACTIVITY AND METHOD THEREFOR
EP2106252A4 (en) NIGHT VISION GLASSES
BRPI0820693A2 (pt) Fotoestabilidade aumentada de avobenzona na presença de óxido de zinco usando emulsificantes à base de fosfato
PL2427193T3 (pl) Zastosowanie inhibitorów pde7 do leczenia zaburzeń ruchu
FR2938934B1 (fr) Verre de lunettes procurant une vision ophtalmique et une vision supplementaire
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
BRPI0909763A2 (pt) soluções oftálmicas tamponadas com fosfato que apresentam eficácia otimizada
BR112013016337A2 (pt) sistema de tratamento médico com fibra óptica
BR112014009479A2 (pt) composição líquida e método de desinfecção da superfície externa de um corpo animal ou humano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.